中国药业2024，Vol.33Issue(8)：95-99,5.DOI:10.3969/j.issn.1006-4931.2024.08.023
双靶向新辅助药物联合不同化疗治疗HER-2阳性乳腺癌临床疗效比较
Comparison of Clinical Efficacy of Dual-Targeted Neoadjuvant Drugs Combined with Different Chemotherapy Regimens in the Treatment of HER-2 Positive Breast Cancer
摘要
Abstract
Objective To investigate the clinical efficacy of dual-targeted neoadjuvant drugs combined with different chemotherapy regimens in the treatment of human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods A total of 110 patients with HER-2 positive breast cancer admitted to the First People's Hospital of Liangshan Yi Autonomous Prefecture from January 2019 to December 2022 were selected and divided into the TcbHP group and the AC-THP group based on different treatment methods,with 55 cases in each group.The patients in the TcbHP group were treated with trastuzumab and pertuzumab combined with taxanes(docetaxel or paclitaxel)and carboplatin for six cycles,with 21 d as a cycle.The patients in the AC-THP group were treated with trastuzumab and pertuzumab combined with anthracyclines(pirarubicin or epirubicin)and cyclophosphamide for eight cycles(trastuzumab and pertuzumab for four cycles,other drugs for four cycles),with 21 d as a cycle.Results The pathological complete remission rate in the TcbHP group was 61.80%,which was slightly higher than 50.90%in the AC-THP group(P>0.05).After treatment,the degree of nausea,vomiting,diarrhea,cardiotoxicity and hand-foot syndrome in the TcbHP group was significantly lower than that in the AC-THP group(P<0.05);the various tumor markers[carbohydrate antigens(CA19-9,CA125,CA153),carcinoembryonic antigen(CEA)]levels were significantly lower than those in the AC-THP group(P<0.05);the left ventricular ejection fraction(LVEF),serum cardiac troponin I(cTnI),creatine kinase isoenzyme-MB(CK-MB),and amino-terminal pro B-type natriuretic peptide(NT-proBNP)levels showed no significant changes(P>0.05),and those were significantly better than those in the AC-THP group(P<0.05).Conclusion The efficacy of TcbHP regimen in the treatment of HER-2 positive breast cancer is similar to that of AC-THP regimen,but the former is more effective in decreasing the tumor marker levels and has lower risk of cardiotoxicity.关键词
化学药物治疗/双靶向药物/新辅助治疗/人类表皮生长因子受体-2/乳腺癌/肿瘤标志物/心脏毒性Key words
chemotherapy/dual-targeted drug/neoadjuvant therapy/human epidermal growth factor receptor-2/breast cancer/tumor marker/cardiotoxicity分类
医药卫生引用本文复制引用
陈方红,高东,张平宇,周杰,黄亮..双靶向新辅助药物联合不同化疗治疗HER-2阳性乳腺癌临床疗效比较[J].中国药业,2024,33(8):95-99,5.基金项目
四川省国际科技创新合作/港澳台科技创新合作项目[2021YFH0138]. （）
